Decoy Therapeutics Inc (DCOY)

$5.80 -0.52 (-8.23%)
Market Cap 3.09M
Revenue (ttm) 0.00
Net Income (ttm) -5.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 14,800
Avg Vol 24,167
Day's Range N/A - N/A
Shares Out 532,000.00
Stochastic %K 9%
Beta 0.37
Analysts Sell
Price Target $30.01

Company Profile

Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio o...

Industry: Biotechnology
Sector: Healthcare
Website: decoytx.com
Address:
One Broadway, 14th Floor, Cambridge, United States
NetNinja
NetNinja Apr. 3 at 6:15 AM
$DCOY This is called the slow spiral of death. I'll give this another month before it's under $1 again.
0 · Reply
focafoca99
focafoca99 Apr. 2 at 7:56 PM
$DCOY has regained compliance with Nasdaq's minimum bid price rule, removing one near-term listing overhang.
0 · Reply
gopiathukuri
gopiathukuri Apr. 2 at 5:03 PM
$DCOY i think we need more volume. Hoping to see some movement since they gained nasdaq compliance officially as of today.
0 · Reply
gopiathukuri
gopiathukuri Apr. 2 at 5:02 PM
$DCOY this is crazy it keeps going down 5-6% with this low volume. Even an order of 140 shares is bringing this down by 5%.
0 · Reply
STACKD0E
STACKD0E Apr. 2 at 1:35 PM
$CODX $DCOY ✨
0 · Reply
RichieGreen
RichieGreen Apr. 1 at 7:12 PM
$DCOY who is selling to get it down that excessive percentage without volume?
0 · Reply
MySwingAmari
MySwingAmari Apr. 1 at 1:28 PM
$DCOY i think that the only interesting news from the yesterday’s 10K report is that they gained again Nasdaq compliance without telling anything in public 😂. Btw a good news although obvious after the RS at the beginning of March
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Apr. 1 at 9:44 AM
$DCOY Q4 '25 Earnings Results & Recap Decoy Therapeutics Inc. reported a net loss of $(12,518,480) for the year ended December 31, 2025, with total operating expenses of $12,613,952 and an accumulated deficit of $(94,442,098).
0 · Reply
Motorhhead
Motorhhead Mar. 31 at 7:30 PM
$DCOY $POLA $OXBR More FANTASTIC short opportunities from the king of short recommendations. Such an absolute treasure here on ST. https://stocktwits.com/beppels/message/649016349
1 · Reply
frankyboyz
frankyboyz Mar. 31 at 7:19 AM
Support and retweet: #frankysWL The one and only Franky’s Watchlist Mar. 31, 2026 Edition TAU - Trend Analytics classes starting soon in March. Come check this out: https://trendanalytics.com/live-classes/ “Afterhours Movers, where tomorrow’s runners are born.” ━━━━━━━━━━━━━━━━━━━━━ $OXBR $POLA $ICU $DCOY and few more... https://x.com/frankyboyz/status/2038878629862502515 Franky
0 · Reply
Latest News on DCOY
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 2, 2026, 9:00 AM EDT - 3 days ago

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Mar 11, 2026, 8:30 AM EDT - 25 days ago

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

Mar 5, 2026, 8:30 AM EST - 4 weeks ago

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

Decoy Therapeutics Joins Webull Corporate Connect Service Platform

Feb 11, 2026, 9:00 AM EST - 7 weeks ago

Decoy Therapeutics Joins Webull Corporate Connect Service Platform

Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Feb 5, 2026, 9:15 AM EST - 2 months ago

Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement

Feb 4, 2026, 9:02 AM EST - 2 months ago

Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

Jan 13, 2026, 8:15 AM EST - 2 months ago

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics

Jan 7, 2026, 8:45 AM EST - 3 months ago

Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics

Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

Dec 19, 2025, 11:12 AM EST - 3 months ago

Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform

Dec 18, 2025, 7:50 AM EST - 3 months ago

Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform

Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study

Dec 1, 2025, 8:00 AM EST - 4 months ago

Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

Nov 19, 2025, 2:42 PM EST - 4 months ago

Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”

Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

Nov 13, 2025, 8:45 AM EST - 5 months ago

Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

Nov 11, 2025, 9:18 AM EST - 5 months ago

Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Oct 13, 2025, 8:45 AM EDT - 6 months ago

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 9, 2025, 8:00 AM EDT - 7 months ago

Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

Aug 14, 2025, 8:30 AM EDT - 8 months ago

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard

Jul 14, 2025, 8:30 AM EDT - 9 months ago

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard

Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

Jul 9, 2025, 8:30 AM EDT - 9 months ago

Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

Feb 3, 2025, 8:00 AM EST - 1 year ago

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge

Jan 13, 2025, 2:12 PM EST - 1 year ago

Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 22, 2024, 4:05 PM EDT - 2 years ago

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Jan 3, 2024, 8:30 AM EST - 2 years ago

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Nov 7, 2023, 8:30 AM EST - 2 years ago

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Jul 11, 2023, 8:30 AM EDT - 2 years ago

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress

Jun 12, 2023, 8:00 AM EDT - 3 years ago

Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 16, 2023, 4:05 PM EDT - 3 years ago

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

May 12, 2023, 8:00 AM EDT - 3 years ago

Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

May 11, 2023, 8:00 AM EDT - 3 years ago

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood

May 9, 2023, 8:17 AM EDT - 3 years ago

Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

May 9, 2023, 8:00 AM EDT - 3 years ago

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164

May 1, 2023, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

Apr 20, 2023, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

Apr 4, 2023, 4:02 PM EDT - 3 years ago

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Mar 27, 2023, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

Mar 15, 2023, 11:00 AM EDT - 3 years ago

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

Feb 16, 2023, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Jan 27, 2023, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Jan 19, 2023, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

Investigators Present Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Dec 13, 2022, 8:01 AM EST - 3 years ago

Investigators Present Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting

Dec 13, 2022, 8:00 AM EST - 3 years ago

Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Dec 1, 2022, 8:00 AM EST - 3 years ago

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 10, 2022, 8:30 AM EST - 3 years ago

Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting

Nov 3, 2022, 9:57 AM EDT - 3 years ago

Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting

Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference

Oct 27, 2022, 8:30 AM EDT - 3 years ago

Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference

NetNinja
NetNinja Apr. 3 at 6:15 AM
$DCOY This is called the slow spiral of death. I'll give this another month before it's under $1 again.
0 · Reply
focafoca99
focafoca99 Apr. 2 at 7:56 PM
$DCOY has regained compliance with Nasdaq's minimum bid price rule, removing one near-term listing overhang.
0 · Reply
gopiathukuri
gopiathukuri Apr. 2 at 5:03 PM
$DCOY i think we need more volume. Hoping to see some movement since they gained nasdaq compliance officially as of today.
0 · Reply
gopiathukuri
gopiathukuri Apr. 2 at 5:02 PM
$DCOY this is crazy it keeps going down 5-6% with this low volume. Even an order of 140 shares is bringing this down by 5%.
0 · Reply
STACKD0E
STACKD0E Apr. 2 at 1:35 PM
$CODX $DCOY ✨
0 · Reply
RichieGreen
RichieGreen Apr. 1 at 7:12 PM
$DCOY who is selling to get it down that excessive percentage without volume?
0 · Reply
MySwingAmari
MySwingAmari Apr. 1 at 1:28 PM
$DCOY i think that the only interesting news from the yesterday’s 10K report is that they gained again Nasdaq compliance without telling anything in public 😂. Btw a good news although obvious after the RS at the beginning of March
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Apr. 1 at 9:44 AM
$DCOY Q4 '25 Earnings Results & Recap Decoy Therapeutics Inc. reported a net loss of $(12,518,480) for the year ended December 31, 2025, with total operating expenses of $12,613,952 and an accumulated deficit of $(94,442,098).
0 · Reply
Motorhhead
Motorhhead Mar. 31 at 7:30 PM
$DCOY $POLA $OXBR More FANTASTIC short opportunities from the king of short recommendations. Such an absolute treasure here on ST. https://stocktwits.com/beppels/message/649016349
1 · Reply
frankyboyz
frankyboyz Mar. 31 at 7:19 AM
Support and retweet: #frankysWL The one and only Franky’s Watchlist Mar. 31, 2026 Edition TAU - Trend Analytics classes starting soon in March. Come check this out: https://trendanalytics.com/live-classes/ “Afterhours Movers, where tomorrow’s runners are born.” ━━━━━━━━━━━━━━━━━━━━━ $OXBR $POLA $ICU $DCOY and few more... https://x.com/frankyboyz/status/2038878629862502515 Franky
0 · Reply
beppels
beppels Mar. 31 at 7:04 AM
$DCOY BEPPELS WL 31.03.: - $DCOY, 7.1 $, 500 k float, 16.7 $ cash per share! ✅ - $POLA, 2.25 $, 1.85 mln float, ripping in ah and overnite, lot of social buzz, last spike took it to nearly 4 $! ✅ - $OXBR, 1.35 $, 7 mln float, top earnings in ah! ✅ 👀 🔥 👀
1 · Reply
JamesPond007
JamesPond007 Mar. 31 at 1:11 AM
$DCOY alright I'm going to help. Dcoy is currently out of Nasdaq compliance. The next catalyst is Nasdaq compliance. Unless they reduce warrants exercise price before that. Happened before. I think this time they will go for compliance first. Good luck.
1 · Reply
SonGoku81
SonGoku81 Mar. 31 at 12:04 AM
$DCOY 8-10$
0 · Reply
JamesPond007
JamesPond007 Mar. 30 at 11:54 PM
$DCOY if you were in Slrx you may recall this management has a rough history of adjusting warrants down below market price. Current exercise price is $18 and it wouldn't surprise me if they adjusted it down to $4.X . Very risky trade. This ticker IS Slrx. Good luck, you need plenty of it
3 · Reply
FuPayMee
FuPayMee Mar. 30 at 9:42 PM
$BTBD and $POLA $DCOY will run tomorrow
0 · Reply
FuPayMee
FuPayMee Mar. 30 at 9:38 PM
$DCOY and $POLA tomorrow's runners
0 · Reply
BadBankofGotham
BadBankofGotham Mar. 30 at 9:20 PM
$DCOY $ILAG $IOTR Ripping now
0 · Reply
beppels
beppels Mar. 30 at 8:53 PM
$DCOY 500 k float, 16.7 $ cash per share, top overniter!
0 · Reply
frankyboyz
frankyboyz Mar. 30 at 8:33 PM
$DCOY fits the theme
1 · Reply
summerblossom
summerblossom Mar. 30 at 7:38 PM
$DCOY
0 · Reply
FuPayMee
FuPayMee Mar. 30 at 7:17 PM
$DCOY currently 7.18 stockwitz is slacking
0 · Reply
FuPayMee
FuPayMee Mar. 30 at 7:09 PM
$DCOY
0 · Reply